(Q34596305)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

title

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

main subject

chronic myeloid leukemia

0 references

0 references

1 reference

dasatinib monohydrate

1 reference

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Jih-Luh Tang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Andreas Hochhaus

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

Carlo Gambacorti-Passerini

13 January 2020

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

J Cortes

1

1 reference

ORCID Public Data File 2021

author name string

D-W Kim

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

E Raffoux

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

G Martinelli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

E Ritchie

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

L Roy

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

S Coutre

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

S Corm

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

H J Khoury

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

T H Brümmendorf

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

M Michallet

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

G Rege-Cambrin

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

J P Radich

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

T Ernst

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

C Zhu

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

J M A Van Tornout

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

M Talpaz

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

publication date

28 August 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

page(s)

2176-2183

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2008.221

13 January 2020

exact match

0 references

cites work

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

The Biology of CML blast crisis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.221

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.221

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18754032%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 January 2020

1023129448

0 references

1 reference